Tunlametinib
As of the edition of 20 October 2026, Tunlametinib is a small molecule: in active development; acts on MAP2K1 and MAP2K2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 19, 2 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Digestive system; Lungs and airways; Hormones; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 1 | 4 | 1 | 0 | 2 |
| Phase 2 | 10 | 2 | 5 | 0 |
| Phase 3 | 2 | 0 | 2 | 0 |
| Phase 4 | 2 | 0 | 2 | 0 |
| All trials | 19 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Kechow Pharma | Lead sponsor of trials | 2017 to now |
| Kechow Pharma | Lead sponsor of trials | 2020 to now |